Last Updated: August 2, 2026

ELAVIL Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Elavil, and what generic alternatives are available?

Elavil is a drug marketed by Astrazeneca and is included in two NDAs.

The generic ingredient in ELAVIL is amitriptyline hydrochloride. There are thirteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the amitriptyline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elavil

A generic version of ELAVIL was approved as amitriptyline hydrochloride by SUN PHARM INDS INC on July 14^th, 1987.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ELAVIL?
What are the global sales for ELAVIL?
What is Average Wholesale Price for ELAVIL?

Summary for ELAVIL

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for ELAVIL

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	ELAVIL	amitriptyline hydrochloride	INJECTABLE;INJECTION	012704-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-007	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Astrazeneca	ELAVIL	amitriptyline hydrochloride	TABLET;ORAL	012703-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.